<DOC>
	<DOCNO>NCT00184613</DOCNO>
	<brief_summary>This trial conduct Europe . The objective study investigate effect safety continously basal deliver insulin aspart give pump versus daily injection insulin glargine .</brief_summary>
	<brief_title>Comparison Insulin Glargine Against Insulin Aspart Infused Under Skin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Subjects type 2 diabetes 2 year Subjects currently treat unchanged insulin glargine dose ( 10 100 unit ) 2 week Subjects currently treat unchanged dose ( ) least 1 month one two Oral Antidiabetic drug BMI 25 40 kg/m2 HbA1c &lt; 9.5 % Known suspect allergy trial product ( ) relate product Previous randomisation trial Pregnancy , breastfeeding , intention become pregnant premenopausal woman judge use adequate contraceptive measure ( Only sterilisation , intra uterine device contraceptive pill consider adequate contraceptive method ) Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . Any significant illness endocrine , cardiac , neurological , malignant pancreatic illness judge Investigator Participation study within last three month</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>